Boston Scientific Claims Its U.S. Defibrillators Enjoy Increased Longevity. FDA Agrees

The U.S. FDA has approved revised product labeling for the Boston Scientific Corporation INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), to reflect increased longevity projections for these devices.

FDA 510(k) Clearance for ViewRay’s MRI-Guided Radiation Therapy System

Cleveland medical device company ViewRay Inc., has received U.S. FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system. The ViewRay system features what the company calls a unique combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer.

FDA Clears Boston Scientific To Expand Indications For CRE™ Balloon To Include Into Stone Extraction

Boston Scientific Corporation has announced the FDA clearance for an expanded use indication for the CRE™ Wireguided Balloon Dilator for endoscopic dilation of the Sphincter of Oddi following sphincterotomy, quite literally opening up the possibility of using it for dilation assisted stone removal.

Bioptigen’s Envisu™ Becomes First OCT System FDA Cleared For Hand-held Paediatric Ophthalmic Imaging

Bioptigen Inc. has received FDA 510(k) clearance to begin marketing its hand-held Envisu Spectral Domain Ophthalmic Imaging System (SDOIS) for patient use. In receiving this regulatory clearance, Bioptigen’s Envisu SDOIS become the first optical coherence tomography(OCT) imaging system commercially available in the United States for hand-held and paediatric imaging.

FDA Approval For Covalon’s IV Clear™ Antimicrobial Silicone Adhesive Film Dressing For Securing Vascular Access Medical Devices

Covalon’s IV Clear™ Silicone dressing is comfortable to wear and remove and contains two antimicrobial components within its adhesive layer, making it a compelling proposition in the market for securement of such as IV access devices. Now the product has FDA clearance to add to its Health Canada approval.

New EU Min Three-Month Anti-Platelet Indication A First For Abbott’s XIENCE PRIME™ and XIENCE V® Drug Eluting Stents

Dual anti-platelet therapy is normally required for 6-12 months after implantation of a stent, with associated risks, costs and general inconvenience. No wonder then that Abbott is sounding pleased with itself as it gains the first indication of its kind to reduce the therapeutic period to a minimum of 3 months based on data from 10,000 patients.

European Approval And Launch Of St.Jude’s EnligHTN™ Renal Denervation System

EuroPCR is being held in Paris right now and is the European focal point for all things cardiovascular. St. Jude Medical, Inc. has chosen the event to announce CE Mark Approval and launch of its EnligHTN™ renal denervation system.

CE Mark and EU Launch Of Boston Scientific’s Innova™ Self-expanding Bare-Metal Peripheral Vascular Stent

Boston Scientific Corporation has issued an announcement confirming CE Mark approval and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee.

FDA 510(k) Clearance for Maquet’s New Mega® Intra-Aortic Balloon Catheter Sizes

MAQUET Cardiovascular LLC has announced that it has received FDA 510(k) clearance for its new MEGA 7.5Fr. 30cc and 40cc intra-aortic balloon (IAB) catheters. These new, larger volume catheters will allow clinicians to provide patients with greater haemodynamic support, regardless of their height.

Most read

Latest

^